Press Releases Jaguar Health, Inc.

Equities

JAGX

US47010C7065

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
0.2921 ^USD	-5.62%		-8.14%	+92.93%

05-06	Jaguar Health Applies for Investigational New Animal Drug Status for Potential Dog Diarrhea Treatment	MT
05-06	Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials and Corporate Updates	05-09	AQ
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion about Microvillus Inclusion Disease	04-30	AQ
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society Congress in Support of Company's Expanding Focus on Cancer Supportive Care	04-23	AQ
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care	04-19	AQ
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders	04-10	AQ
Jaguar Health Granted Extension until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement	04-09	AQ
Jaguar Health : Corporate Presentation – April 1, 2024	04-05	PU
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International	04-03	AQ
Jaguar Health Reports 2023 Financial Results	04-02	AQ
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials and Corporate Updates	03-28	AQ
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance	02-26	AQ
Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief	02-15	AQ
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea	02-13	AQ
Magdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions	01-31	AQ
Jaguar Health to Present January 31 at the Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference	01-30	AQ
Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health's Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea	01-26	AQ
Jaguar Health : Corporate Presentation – December 11, 2023	12-19	PU
A Majority of Subjects in Jaguar Health s Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II	12-12	AQ
Jaguar Health - Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals, Published on San Antonio Breast Cancer Symposium Website	12-07	AQ
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs	12-05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Jaguar Health, Inc.

Equities

JAGX

US47010C7065

Press Releases

Filters